# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TransCode Therapeutics, Inc. (NASDAQ:RNAZ), (the "Company"), an RNA oncology company committed to more effectively trea...
- SEC Filing
HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...